Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULAATE: Alpha-1 antitrypsin to prevent acute graft-versus-host disease after hematopoietic cell transplant
jRCT2011210064Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of alpha-1-proteinase inhibitor in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by CSL Limited. Primary endpoint: Grade II-IV acute GVHD-free survival through 180 days after HCT. Started Jul 2022; status: active, not recruiting.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on jRCT2011210064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210064.